Research & Literature

Nail psoriasis as a predictor of the development of psoriatic arthritis.

Raposo I, Torres T

Actas dermo-sifiliograficas 2015; (106(6)):452-7.

Psoriatic T cells reduce epidermal turnover time and affect cell proliferation contributed from differential gene expression.

Li J, Li X, Hou R, et al.

The Journal of dermatology 2015; (42(9)):874-80 doi:10.1111/1346-8138.12961.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Papp K, Reich K, Leonardi CL, et al.

Journal of the American Academy of Dermatology 2015; (73(1)):37-49.

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.

Steenholdt C, Frederiksen MT, Bendtzen K, et al.

Journal of clinical gastroenterology 2016; (50(6)):483-9 doi:10.1097/MCG.0000000000000375.

Apremilast: A Review in Psoriasis and Psoriatic Arthritis.

Deeks ED

Drugs 2015; (75(12)):1393-403 doi:10.1007/s40265-015-0439-1.

A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis.

Wu L, Chen X, Zhao J, et al.

The Journal of experimental medicine 2015; (212(10)):1571-87 doi:10.1084/jem.20150204.

The skin in psoriasis: assessment and challenges.

Oji V, Luger TA

Clinical and experimental rheumatology 2015; (33(5 Suppl 93)):S14-9.

Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

Murdaca G, Spanò F, Contatore M, et al.

Expert opinion on drug safety 2016; (15(1)):43-52 doi:10.1517/14740338.2016.1112375.

Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.

Kin KC, Hill D, Feldman SR

Expert review of clinical pharmacology 2016; (9(6)):789-97 doi:10.1080/17512433.2016.1179574.

Clinical meaningfulness of complete skin clearance in psoriasis.

Strober B, Papp KA, Lebwohl M, et al.

Journal of the American Academy of Dermatology 2016; (75(1)):77-82.e7.

Treatment Options for Pediatric Psoriasis.

Madiraca D, Šitum M, Prkačin I, Ožanić Bulić S

Acta dermatovenerologica Croatica : ADC 2016; (24(3)):175-80.

Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.

Raychaudhuri SP, Wilken R, Sukhov AC, et al.

Journal of autoimmunity 2017; (76()):21-37 doi:10.1016/j.jaut.2016.10.009.

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

Reich K, Pinter A, Lacour JP, et al.

The British journal of dermatology 2017; (177(4)):1014-1023 doi:10.1111/bjd.15666.

Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis.

Dua I, Aggarwal K, Jain VK

Photodermatology, photoimmunology & photomedicine 2017; (33(5)):275-281 doi:10.1111/phpp.12324.

Pustular Palmoplantar Psoriasis Successfully Treated with Nb-UVB Monochromatic Excimer Light: A Case-Report.

Gianfaldoni S, Tchernev G, Wollina U, Lotti T

Open access Macedonian journal of medical sciences 2017; (5(4)):462-466 doi:10.3889/oamjms.2017.080.

Psoriasis pathogenesis and the development of novel targeted immune therapies.

Hawkes JE, Chan TC, Krueger JG

The Journal of allergy and clinical immunology 2017; (140(3)):645-653 doi:10.1016/j.jaci.2017.07.004.

Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'.

Audureau E, Roux F, Lons Danic D, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(11)):1950-1953 doi:10.1111/jdv.14861.

Dactylitis: A hallmark of psoriatic arthritis.

Kaeley GS, Eder L, Aydin SZ, et al.

Seminars in arthritis and rheumatism 2018; (48(2)):263-273 doi:10.1016/j.semarthrit.2018.02.002.

An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.

Xu M, Lu H, Lee YH, et al.

Immunity 2018; (48(4)):787-798.e4 doi:10.1016/j.immuni.2018.03.019.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, et al.

Journal of the American Academy of Dermatology 2019; (80(1)):251-265.e19 doi:10.1016/j.jaad.2018.06.027.

Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery.

Gauld SB, Gauvin D, Olson L, et al.

Journal of dermatological science 2018; (92(1)):45-53 doi:10.1016/j.jdermsci.2018.08.001.

Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival.

Costanzo A, Malara G, Pelucchi C, et al.

Dermatology (Basel, Switzerland) 2018; (234(1-2)):1-12 doi:10.1159/000488586.

Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study.

Preda C, Fulger L, Gheorghe L, et al.

Current health sciences journal 2016; (42(2)):115-124 doi:10.12865/CHSJ.42.02.01.

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.

Tournier A, Khemis A, Maccari F, et al.

Annales de dermatologie et de venereologie 2019; (146(2)):106-114 doi:10.1016/j.annder.2018.11.011.

IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.

Krueger JG, Wharton KA, Schlitt T, et al.

The Journal of allergy and clinical immunology 2019; (144(3)):750-763 doi:10.1016/j.jaci.2019.04.029.

Transepidermal Water Loss in Psoriasis: A Case-control Study.

Nikam VN, Monteiro RC, Dandakeri S, Bhat RM

Indian dermatology online journal 2019; (10(3)):267-271 doi:10.4103/idoj.IDOJ_180_18.

The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.

D'Adamio S, Silvaggio D, Lombardo P, et al.

Expert opinion on drug safety 2019; (18(11)):1031-1041 doi:10.1080/14740338.2019.1663168.

Anti IL-17 in psoriasis.

Ly K, Smith MP, Thibodeaux Q, et al.

Expert review of clinical immunology 2019; (15(11)):1185-1194 doi:10.1080/1744666X.2020.1679625.

Keratinocyte-derived IκBζ drives psoriasis and associated systemic inflammation.

Lorscheid S, Müller A, Löffler J, et al.

JCI insight 2019; (4(22)).

A novel vehicle for the treatment of psoriasis.

Dattola A, Silvestri M, Bennardo L, et al.

Dermatologic therapy 2020; (33(1)):e13185 doi:10.1111/dth.13185.

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities.

Gisondi P, Bellinato F, Girolomoni G, Albanesi C

Frontiers in pharmacology 2020; (11()):117 doi:10.3389/fphar.2020.00117.

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

Armstrong AW, Read C

JAMA 2020; (323(19)):1945-1960 doi:10.1001/jama.2020.4006.

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.

Blauvelt A, Leonardi C, Elewski B, et al.

The British journal of dermatology 2021; (184(6)):1047-1058 doi:10.1111/bjd.19509.

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.

Augustin M, Lambert J, Zema C, et al.

JAMA dermatology 2020; (156(12)):1344-1353 doi:10.1001/jamadermatol.2020.3617.

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.

Gisondi P, Talamonti M, Chiricozzi A, et al.

Dermatology and therapy 2021; (11(1)):235-252 doi:10.1007/s13555-020-00475-8.

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.

Menter A, Krueger GG, Paek SY, et al.

Dermatology and therapy 2021; (11(2)):385-400 doi:10.1007/s13555-021-00483-2.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.

Nast A, Smith C, Spuls PI, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(2)):281-317 doi:10.1111/jdv.16926.

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.

Reich K, Mrowietz U, Menter A, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(12)):2409-2414 doi:10.1111/jdv.17520.

Assessment of Selected Matrix Metalloproteinases (MMPs) and Correlation with Cytokines in Psoriatic Patients.

Michalak-Stoma A, Bartosińska J, Raczkiewicz D, et al.

Mediators of inflammation 2021; (2021()):9913798 doi:10.1155/2021/9913798.

Prevalence of psoriatic arthritis among patients with plaque psoriasis: a Brazilian retrospective study.

Gamonal SBL, Gamonal ACC, Brandão MAF, et al.

Sao Paulo medical journal = Revista paulista de medicina 2021; (139(5)):476-480 doi:10.1590/1516-3180.2020.0629.16032021.

Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients.

Piros ÉA, Szabó Á, Rencz F, et al.

Life (Basel, Switzerland) 2021; (11(9)) doi:10.3390/life11090919.

The biological basis of disease recurrence in psoriasis: a historical perspective and current models.

Puig L, Costanzo A, Muñoz-Elías EJ, et al.

The British journal of dermatology 2022; (186(5)):773-781 doi:10.1111/bjd.20963.

Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study.

Löfvendahl S, Norlin JM, Schmitt-Egenolf M

The British journal of dermatology 2022; (186(6)):970-976 doi:10.1111/bjd.20966.

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.

Gooderham M, Pinter A, Ferris LK, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(6)):855-865 doi:10.1111/jdv.18010.

Erythrodermic Psoriasis and Staph-Infective Endocarditis-A Conundrum in Succession.

Patel A, Venter F, Grewal K, et al.

Journal of investigative medicine high impact case reports 2022; (10()):23247096221105243 doi:10.1177/23247096221105243.

Tapinarof Cream 1%: First Approval.

Keam SJ

Drugs 2022; (82(11)):1221-1228 doi:10.1007/s40265-022-01748-6.

Palmoplantar Plaque Psoriasis is Associated with Diabetes, Hypertension, Obesity, and Metabolic Syndrome-A Case-Control Study.

Rathod A, Neema S, Radhakrishnan S, et al.

Indian dermatology online journal 2022; (13(5)):606-610 doi:10.4103/idoj.idoj_59_22.

IL-17 Signaling in Keratinocytes Orchestrates the Defense against Staphylococcus aureus Skin Infection.

Moos S, Regen T, Wanke F, et al.

The Journal of investigative dermatology 2023; (143(7)):1257-1267.e10 doi:10.1016/j.jid.2023.01.016.

Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.

Terui H, Asano Y

Journal of clinical medicine 2023; (12(3)) doi:10.3390/jcm12031162.

Psoriasis: Rediscovering the meaning of the name.

Balestri R, Magnano M, Rech G

Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(4)):647-648 doi:10.1111/jdv.18950.

The use of ultrasound to detect enthesitis as a potential guide for intervention in patients with psoriasis at risk of psoriatic arthritis: a systematic review.

Norden A, Oulee A, Ivanic M, et al.

International journal of dermatology 2023; (62(8)):973-979 doi:10.1111/ijd.16645.

Comparative evaluation of efficacy and safety of calcipotriol versus calcitriol ointment, both in combination with narrow-band ultraviolet B phototherapy in the treatment of stable plaque psoriasis.

Chakraborty D, Aggarwal K

Photodermatology, photoimmunology & photomedicine 2023; (39(5)):512-519 doi:10.1111/phpp.12893.

Enthesopathy in patients with nail psoriasis - a cross-sectional evaluation of clinical, onychoscopic and ultrasonographic features.

Bhoi AK, Grover C, Singal A, Tandon A

Indian journal of dermatology, venereology and leprology 2023; (89(6)):854-861.

Impact of Alcohol Consumption, Smoking, and Diet on the Severity of Plaque Psoriasis: A Comprehensive Assessment using Clinical Scales and Quality of Life Measures.

Michalski P, Palazzo-Michalska V, Michalska-Bańkowska A, et al.

Medical science monitor : international medical journal of experimental and clinical research 2023; (29()):e941255 doi:10.12659/MSM.941255.

Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis.

Asenjo-Lobos C, González L, Bulnes JF, et al.

Clinical research in cardiology : official journal of the German Cardiac Society 2024; (113(2)):246-259 doi:10.1007/s00392-023-02291-4.

Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score.

Husein-ElAhmed H, Husein-ElAhmed S

Clinical and experimental dermatology 2024; (49(10)):1148-1155 doi:10.1093/ced/llae131.

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.

Chanchlani N, Lin S, Bewshea C, et al.

The lancet. Gastroenterology & hepatology 2024; (9(6)):521-538 doi:10.1016/S2468-1253(24)00044-X.

Relationship Between Family History and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study from China.

Jiang F, Lu L, Wang S, et al.

Clinical, cosmetic and investigational dermatology 2024; (17()):891-900 doi:10.2147/CCID.S453078.

Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis.

Wang Y, Cui Y, Zheng Z

Indian journal of dermatology 2024; (69(2)):178-180 doi:10.4103/ijd.ijd_155_23.

IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis.

Aggarwal P, Fleischer AB

Journal of clinical medicine 2024; (13(17)) doi:10.3390/jcm13175139.

Psoriatic nail involvement in Malaysia: A 14-year registry review (2007-2020).

Tan WF, Robinson S, Tang MM,

Clinics in dermatology 2024; (42(6)):616-624 doi:10.1016/j.clindermatol.2024.09.017.

Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.

Augustin M, Gottlieb AB, Lebwohl M, et al.

Dermatology and therapy 2024; (14(10)):2841-2857 doi:10.1007/s13555-024-01261-6.

Metabolic Syndrome in Psoriasis Patients-an Observational Study.

Dascǎlu RC, Bǎrbulescu AL, Dinescu ŞC, et al.

Current health sciences journal 2024; (50(2)):215-222 doi:10.12865/CHSJ.50.02.06.

Apremilast: First Pediatric Approval.

Blair HA

Paediatric drugs 2025; (27(1)):119-124 doi:10.1007/s40272-024-00668-0.

Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases.

Choi B, Li HO, Glassman SJ

SAGE open medical case reports 2025; (13()):2050313X251317763 doi:10.1177/2050313X251317763.

Quality of life of patients with pustular psoriasis is inferior to that of patients with plaque psoriasis in Japan: A multicenter study with questionnaires, the short Form-36, and other patient-reported outcomes.

Imafuku S, Satoh A, Arima H, et al.

The Journal of dermatology 2025; (52(4)):682-694 doi:10.1111/1346-8138.17629.

Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn's Disease.

Rueda García JL, Suárez-Ferrer C, Amiama Roig C, et al.

Therapeutic advances in gastroenterology 2025; (18()):17562848251324226 doi:10.1177/17562848251324226.

Molecular Link Between Psoriasis and Depression-Update on Pathophysiology.

Hołdrowicz A, Żebrowska A

International journal of molecular sciences 2025; (26(6)) doi:10.3390/ijms26062467.

The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis.

Jiang W, Li Q, Zheng W

Archives of dermatological research 2025; (317(1)):643 doi:10.1007/s00403-025-04174-2.

Psychiatric disorders in psoriatic patients: a cross-sectional study in multi-government hospitals.

Abdel-Azim AA, Ismail RM, Ahmed Elshabasy HS, Pessar DAH

Archives of dermatological research 2025; (317(1)):722 doi:10.1007/s00403-025-04181-3.

Efficacy and Safety of IL-17 and IL-23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real-World Study.

Hacınecipoğlu F, Çelik G, Kartal SP

The Journal of dermatology 2025; (52(7)):1166-1174 doi:10.1111/1346-8138.17755.

The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris.

Çelik MS, Aktaş H

Irish journal of medical science 2025; (194(4)):1329-1334 doi:10.1007/s11845-025-03969-6.

Guttate Psoriasis: Another Kid With an Itchy Rash.

Dodge T

Advanced emergency nursing journal 2025; (47(3)):193-197 doi:10.1097/TME.0000000000000576.

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.

Papp KA, Vender R, Purdy K, et al.

Dermatology and therapy 2025; (15(9)):2615-2629 doi:10.1007/s13555-025-01463-6.

The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome.

Tang L, Bi H, Lin K, et al.

Psoriasis (Auckland, N.Z.) 2025; (15()):411-428 doi:10.2147/PTT.S535900.

Unveiling the Metabolic Burden: A Clinicopathological Study of Chronic Plaque Psoriasis and Its Association With Metabolic Syndrome.

Shah S, Parikh K, Shah ML, Kothari A

Cureus 2025; (17(8)):e89289 doi:10.7759/cureus.89289.

An Association Analysis of Anxiety and Psoriasis: Based on the NHANES Database.

Bai J, Ma Y

Brain and behavior 2025; (15(9)):e70817 doi:10.1002/brb3.70817.

The Heart of Psoriasis: Cardiovascular Alterations and Common Inflammatory Mechanisms.

Santillo E, Marini L, Cardinali L

Current cardiology reviews 2026; (22(4)):e1573403X412277 doi:10.2174/011573403X412277250911072530.

Recognizing Guttate Psoriasis in Primary Care: A Pediatric Case Report Following a Streptococcal Pharyngitis Infection.

Vanderwerff T, Newton L

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 2026; (40(3)):e105-e109 doi:10.1016/j.pedhc.2025.09.012.

Efficacy and safety of biologics in erythrodermic psoriasis: a systematic review and single-arm meta-analysis.

Gao L, Shen L, Yan H, et al.

Frontiers in immunology 2025; (16()):1714587 doi:10.3389/fimmu.2025.1714587.

Laboratory monitoring in patients with moderate to severe plaque psoriasis.

Fenkel JM, Osborne JA, Armstrong AW, et al.

The Journal of dermatological treatment 2025; (36(1)):2583227 doi:10.1080/09546634.2025.2583227.

Microbiological analysis of patients with inverse and plaque-type psoriasis.

Ustuner P, Ceylan AN

BMC microbiology 2025; (26(1)):24 doi:10.1186/s12866-025-04594-0.

Distributive Shock in a Case of Erythrodermic Psoriasis Associated With Bacteremia From Multiple Opportunistic Pathogens: A Case Report.

Özel H

Cureus 2025; (17(12)):e99131 doi:10.7759/cureus.99131.

[Moderate-severe psoriasis and associated comorbidity in patients on biologic therapy: implications for primary care].

González Fernández J, Ara-Martín M, Ruiz-Cortegoso AP, Prieto-Torres L

Semergen 2026; (52(3)):102720 doi:10.1016/j.semerg.2026.102720.

Immunoregulation by DC and T cells in psoriasis with probable immunotherapeutic approaches.

Kundu S, Paul R, Chakraborty K

International reviews of immunology 2026; (45(4)):213-228 doi:10.1080/08830185.2026.2650139.

IL-23 blockade: A strategy for managing pain-related inflammatory diseases.

García-Domínguez M

International review of cell and molecular biology 2026; (401()):225-245 doi:10.1016/bs.ircmb.2026.02.005.

T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes.

Schön MP

Frontiers in immunology 2026; (17()):1880068 doi:10.3389/fimmu.2026.1880068.

A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.

Zhou W, Li Z, Liu X, et al.

American journal of clinical and experimental immunology 2026; (15(3)):156-192 doi:10.62347/YBMA7699.

Erythrodermic psoriasis with early diagnostic uncertainty requiring multidisciplinary rheumatological management: A case report.

Danagara SR, Selvarajan T, Kannekanti L, et al.

Medicine international 2026; (6(5)):46 doi:10.3892/mi.2026.330.

Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies.

Xie W, Chen T, Chen Y, Xiao S

American journal of clinical dermatology 2026; doi:10.1007/s40257-026-01065-8.